Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

The safety and immunogenicity of a new candidate tuberculosis (TB) vaccine, FP85A was evaluated alone and in heterologous prime-boost regimes with another candidate TB vaccine, MVA85A. This was an open label, non-controlled, non-randomized Phase I clinical trial. Healthy previously BCG-vaccinated ad...

Full description

Bibliographic Details
Main Authors: Rowland, R, Pathan, A, Satti, I, Poulton, I, Matsumiya, M, Whittaker, M, Minassian, A, O'Hara, G, Hamill, M, Scott, J, Harris, SA, Poyntz, H, Bateman, C, Meyer, J, Williams, N, Gilbert, S, Lawrie, A, Hill, A, Mcshane, H
Format: Journal article
Language:English
Published: 2013

Similar Items